Summary:
- Cytokinetics, a biopharmaceutical company, has reported positive data from its Phase 3 clinical trial of aficamten, a drug candidate for the treatment of hypertrophic cardiomyopathy (HCM).
- The data showed that aficamten was able to significantly improve cardiac function and reduce symptoms in patients with HCM, a condition characterized by thickening of the heart muscle.
- These results position aficamten as a potential alternative to beta-blockers, the current standard of care for HCM, and could lead to the development of a new treatment option for this serious heart condition.